CRDF Stock — Cardiff Oncology Inc.: Cash, EV, Pipeline

Share price

$1.37

Market cap

$106.6M

Cash

$43.6M

Enterprise value

$63.0M

Balance sheet

Cash	$43.6M
Debt	$0.0M
Net cash	$43.6M
Enterprise value	$63.0M
Basic shares	68.5M shares
Fully diluted shares	97.1M shares
Fully diluted market cap	$133.0M
Cash per share	$0.64

Cash figures as of 2026-07-16. Database snapshot: 2026-09-21.

Price history

Loading CRDF daily closes…

Loading price history…

Pipeline assets

Onvansertib

Phase 2 · Active Modality: small molecule

Aliases NMS-1286937

Target PLK1

Partnerships Nerviano Medical Sciences: license (Mar 2017); up to $15M development milestones + commercial milestones + royalties

Indications

RAS-mutated metastatic colorectal cancer (1L) (Phase 2)
Metastatic pancreatic ductal adenocarcinoma (Phase 2)
Small cell lung cancer (Phase 2)
Metastatic triple-negative breast cancer (Phase 1)
CMML / MDS-MPN (Phase 1)

Status note Oral PLK1 inhibitor. Lead Phase 2 CRDF-004 in 1L RAS-mutated mCRC; 30 mg + FOLFIRI/bev dose selected for registrational Phase 3 CRDF-005 (designed after Apr 2026 End-of-Phase 2 FDA meeting). Other indications explored via investigator-initiated trials. Risk factor notes a dispute over alleged termination of the NMS license.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04005690	Early Phase 1	Recruiting	Collaborator	OHSU Knight Cancer Institute	—	Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8	—

Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for OHSU Knight Cancer Institute on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

CRDF — Cardiff Oncology Inc.

Balance sheet

Price history

Pipeline assets

Active clinical trials